Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Development of New Antimicrobials for Urogenital Gonorrhea Therapy: Clinical Trial Design Considerations.

Hook EW, Newman L, Drusano G, Evans S, Handsfield HH, Jerse AE, Kong FYS, Lee JY, Taylor SN, Deal C.

Clin Infect Dis. 2019 Sep 20. pii: ciz899. doi: 10.1093/cid/ciz899. [Epub ahead of print]

PMID:
31538646
2.

Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap.

Gottlieb SL, Jerse AE, Delany-Moretlwe S, Deal C, Giersing BK.

Sex Health. 2019 Sep 3. doi: 10.1071/SH19060. [Epub ahead of print]

PMID:
31476278
3.

Could Dampening Expression of the Neisseria gonorrhoeae mtrCDE-Encoded Efflux Pump Be a Strategy To Preserve Currently or Resurrect Formerly Used Antibiotics To Treat Gonorrhea?

Chen S, Connolly KL, Rouquette-Loughlin C, D'Andrea A, Jerse AE, Shafer WM.

MBio. 2019 Aug 13;10(4). pii: e01576-19. doi: 10.1128/mBio.01576-19.

4.

Commensal Neisseria Kill Neisseria gonorrhoeae through a DNA-Dependent Mechanism.

Kim WJ, Higashi D, Goytia M, Rendón MA, Pilligua-Lucas M, Bronnimann M, McLean JA, Duncan J, Trees D, Jerse AE, So M.

Cell Host Microbe. 2019 Aug 14;26(2):228-239.e8. doi: 10.1016/j.chom.2019.07.003. Epub 2019 Aug 1.

PMID:
31378677
5.

Female Mouse Model of Neisseria gonorrhoeae Infection.

Raterman EL, Jerse AE.

Methods Mol Biol. 2019;1997:413-429. doi: 10.1007/978-1-4939-9496-0_24.

PMID:
31119637
6.

Neisseria gonorrhoeae MlaA influences gonococcal virulence and membrane vesicle production.

Baarda BI, Zielke RA, Le Van A, Jerse AE, Sikora AE.

PLoS Pathog. 2019 Mar 7;15(3):e1007385. doi: 10.1371/journal.ppat.1007385. eCollection 2019 Mar.

7.

Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant Neisseria gonorrhoeae Strains in the Gonorrhea Mouse Model.

Connolly KL, Eakin AE, Gomez C, Osborn BL, Unemo M, Jerse AE.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01644-18. doi: 10.1128/AAC.01644-18. Print 2019 Mar.

8.

Lipid-Modified Azurin of Neisseria gonorrhoeae Is Not Surface Exposed and Does Not Interact With the Nitrite Reductase AniA.

Baarda BI, Zielke RA, Jerse AE, Sikora AE.

Front Microbiol. 2018 Nov 27;9:2915. doi: 10.3389/fmicb.2018.02915. eCollection 2018.

9.

SliC is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during Neisseria gonorrhoeae infection.

Zielke RA, Le Van A, Baarda BI, Herrera MF, Acosta CJ, Jerse AE, Sikora AE.

PLoS Pathog. 2018 Jul 5;14(7):e1007081. doi: 10.1371/journal.ppat.1007081. eCollection 2018 Jul.

10.

cis- and trans-Acting Factors Influence Expression of the norM-Encoded Efflux Pump of Neisseria gonorrhoeae and Levels of Gonococcal Susceptibility to Substrate Antimicrobials.

Rouquette-Loughlin CE, Dhulipala V, Reimche JL, Raterman E, Begum AA, Jerse AE, Shafer WM.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00821-18. doi: 10.1128/AAC.00821-18. Print 2018 Aug.

11.

First description of a cefixime- and ciprofloxacin-resistant Neisseria gonorrhoeae isolate with mutations in key antimicrobial susceptibility-determining genes from the country of Georgia.

Washington MA, Jerse AE, Rahman N, Pilligua-Lucas M, Garges EC, Latif NH, Akhvlediani T.

New Microbes New Infect. 2018 Apr 25;24:47-51. doi: 10.1016/j.nmni.2018.04.004. eCollection 2018 Jul.

12.

Biological feasibility and importance of a gonorrhea vaccine for global public health.

Vincent LR, Jerse AE.

Vaccine. 2018 Apr 18. pii: S0264-410X(18)30278-0. doi: 10.1016/j.vaccine.2018.02.081. [Epub ahead of print]

13.

In Vivo-Selected Compensatory Mutations Restore the Fitness Cost of Mosaic penA Alleles That Confer Ceftriaxone Resistance in Neisseria gonorrhoeae.

Vincent LR, Kerr SR, Tan Y, Tomberg J, Raterman EL, Dunning Hotopp JC, Unemo M, Nicholas RA, Jerse AE.

MBio. 2018 Apr 3;9(2). pii: e01905-17. doi: 10.1128/mBio.01905-17.

14.

Aminomethyl Spectinomycins as Therapeutics for Drug-Resistant Gonorrhea and Chlamydia Coinfections.

Butler MM, Waidyarachchi SL, Connolly KL, Jerse AE, Chai W, Lee RE, Kohlhoff SA, Shinabarger DL, Bowlin TL.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00325-18. doi: 10.1128/AAC.00325-18. Print 2018 May.

15.

In Vitro Susceptibility of Neisseria gonorrhoeae Strains to Mupirocin, an Antibiotic Reformulated for Parenteral Administration in Nanoliposomes.

Cern A, Connolly KL, Jerse AE, Barenholz Y.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02377-17. doi: 10.1128/AAC.02377-17. Print 2018 Apr.

16.

Neisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development.

Rice PA, Shafer WM, Ram S, Jerse AE.

Annu Rev Microbiol. 2017 Sep 8;71:665-686. doi: 10.1146/annurev-micro-090816-093530. Review.

PMID:
28886683
17.

Structure-based design of ferritin nanoparticle immunogens displaying antigenic loops of Neisseria gonorrhoeae.

Wang L, Xing D, Le Van A, Jerse AE, Wang S.

FEBS Open Bio. 2017 Jul 24;7(8):1196-1207. doi: 10.1002/2211-5463.12267. eCollection 2017 Aug.

18.

Both MisR (CpxR) and MisS (CpxA) Are Required for Neisseria gonorrhoeae Infection in a Murine Model of Lower Genital Tract Infection.

Gangaiah D, Raterman EL, Wu H, Fortney KR, Gao H, Liu Y, Jerse AE, Spinola SM.

Infect Immun. 2017 Aug 18;85(9). pii: e00307-17. doi: 10.1128/IAI.00307-17. Print 2017 Sep.

19.

Control of gdhR Expression in Neisseria gonorrhoeae via Autoregulation and a Master Repressor (MtrR) of a Drug Efflux Pump Operon.

Rouquette-Loughlin CE, Zalucki YM, Dhulipala VL, Balthazar JT, Doyle RG, Nicholas RA, Begum AA, Raterman EL, Jerse AE, Shafer WM.

MBio. 2017 Apr 11;8(2). pii: e00449-17. doi: 10.1128/mBio.00449-17.

20.

Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model.

Liu Y, Hammer LA, Liu W, Hobbs MM, Zielke RA, Sikora AE, Jerse AE, Egilmez NK, Russell MW.

Mucosal Immunol. 2017 Nov;10(6):1594-1608. doi: 10.1038/mi.2017.11. Epub 2017 Mar 1.

21.

Alanine 501 Mutations in Penicillin-Binding Protein 2 from Neisseria gonorrhoeae: Structure, Mechanism, and Effects on Cephalosporin Resistance and Biological Fitness.

Tomberg J, Fedarovich A, Vincent LR, Jerse AE, Unemo M, Davies C, Nicholas RA.

Biochemistry. 2017 Feb 28;56(8):1140-1150. doi: 10.1021/acs.biochem.6b01030. Epub 2017 Feb 16.

22.

Antibacterial activity of resazurin-based compounds against Neisseria gonorrhoeae in vitro and in vivo.

Schmitt DM, Connolly KL, Jerse AE, Detrick MS, Horzempa J.

Int J Antimicrob Agents. 2016 Oct;48(4):367-72. doi: 10.1016/j.ijantimicag.2016.06.009. Epub 2016 Jul 19.

23.

Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop "Gonorrhea Vaccines: the Way Forward".

Wetzler LM, Feavers IM, Gray-Owen SD, Jerse AE, Rice PA, Deal CD.

Clin Vaccine Immunol. 2016 Aug 5;23(8):656-63. doi: 10.1128/CVI.00230-16. Print 2016 Aug. Review.

24.

Proteomics-driven Antigen Discovery for Development of Vaccines Against Gonorrhea.

Zielke RA, Wierzbicki IH, Baarda BI, Gafken PR, Soge OO, Holmes KK, Jerse AE, Unemo M, Sikora AE.

Mol Cell Proteomics. 2016 Jul;15(7):2338-55. doi: 10.1074/mcp.M116.058800. Epub 2016 May 2.

25.

The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps.

Gottlieb SL, Deal CD, Giersing B, Rees H, Bolan G, Johnston C, Timms P, Gray-Owen SD, Jerse AE, Cameron CE, Moorthy VS, Kiarie J, Broutet N.

Vaccine. 2016 Jun 3;34(26):2939-2947. doi: 10.1016/j.vaccine.2016.03.111. Epub 2016 Apr 19. Review.

26.

Augmentation of Cationic Antimicrobial Peptide Production with Histone Deacetylase Inhibitors as a Novel Epigenetic Therapy for Bacterial Infections.

Yedery RD, Jerse AE.

Antibiotics (Basel). 2015 Jan 12;4(1):44-61. doi: 10.3390/antibiotics4010044. Review.

27.

Overproduction of the MtrCDE efflux pump in Neisseria gonorrhoeae produces unexpected changes in cellular transcription patterns.

Ohneck EA, Goytia M, Rouquette-Loughlin CE, Joseph SJ, Read TD, Jerse AE, Shafer WM.

Antimicrob Agents Chemother. 2015 Jan;59(1):724-6. doi: 10.1128/AAC.04148-14. Epub 2014 Nov 3.

28.

Phase-variable expression of lptA modulates the resistance of Neisseria gonorrhoeae to cationic antimicrobial peptides.

Kandler JL, Joseph SJ, Balthazar JT, Dhulipala V, Read TD, Jerse AE, Shafer WM.

Antimicrob Agents Chemother. 2014 Jul;58(7):4230-3. doi: 10.1128/AAC.03108-14. Epub 2014 May 12.

29.

Phosphoethanolamine decoration of Neisseria gonorrhoeae lipid A plays a dual immunostimulatory and protective role during experimental genital tract infection.

Packiam M, Yedery RD, Begum AA, Carlson RW, Ganguly J, Sempowski GD, Ventevogel MS, Shafer WM, Jerse AE.

Infect Immun. 2014 Jun;82(6):2170-9. doi: 10.1128/IAI.01504-14. Epub 2014 Mar 31.

30.

Expanded sexually transmitted infection surveillance efforts in the United States military: a time for action.

Sánchez JL, Agan BK, Tsai AY, Macalino GE, Wurapa E, Mbuchi M, Dueger E, Horton KC, Montano-Torres SM, Tilley DH, Saylors KE, Puplampu N, Duplessis CC, Harrison DJ, Putnam SD, Garges EC, Espinosa BJ, Dejli J, Meyers M, Yingst SL, Jerse AE, Maktabi HH, Burke RL, Jordan NN, Nowak G, Hsu K, Soge OO, Holmes KK, McClelland RS, MacDonald MR, Pavlin JA, Gaydos JC, Tramont EC.

Mil Med. 2013 Dec;178(12):1271-80. doi: 10.7205/MILMED-D-13-00137. Review. No abstract available.

PMID:
24306007
31.

Vaccine research for gonococcal infections: where are we?

Jerse AE, Deal CD.

Sex Transm Infect. 2013 Dec;89 Suppl 4:iv63-8. doi: 10.1136/sextrans-2013-051225. Review.

PMID:
24243883
32.

Lipid A's structure mediates Neisseria gonorrhoeae fitness during experimental infection of mice and men.

Hobbs MM, Anderson JE, Balthazar JT, Kandler JL, Carlson RW, Ganguly J, Begum AA, Duncan JA, Lin JT, Sparling PF, Jerse AE, Shafer WM.

MBio. 2013 Nov 19;4(6):e00892-13. doi: 10.1128/mBio.00892-13.

33.

Vaccines against gonorrhea: current status and future challenges.

Jerse AE, Bash MC, Russell MW.

Vaccine. 2014 Mar 20;32(14):1579-87. doi: 10.1016/j.vaccine.2013.08.067. Epub 2013 Sep 6.

34.

Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations.

Kunz AN, Begum AA, Wu H, D'Ambrozio JA, Robinson JM, Shafer WM, Bash MC, Jerse AE.

J Infect Dis. 2012 Jun 15;205(12):1821-9. doi: 10.1093/infdis/jis277. Epub 2012 Apr 5.

35.

The natural history of incident gonococcal infection in adolescent women: similar observations in a female mouse model of gonococcal and chlamydial coinfection.

Vonck Stankowski R, Cole JG, Jerse AE.

Sex Transm Dis. 2012 Mar;39(3):238. doi: 10.1097/OLQ.0b013e3182471974. No abstract available.

PMID:
22337114
36.

Protective role of Toll-like receptor 4 in experimental gonococcal infection of female mice.

Packiam M, Wu H, Veit SJ, Mavrogiorgos N, Jerse AE, Ingalls RR.

Mucosal Immunol. 2012 Jan;5(1):19-29. doi: 10.1038/mi.2011.38. Epub 2011 Sep 21.

37.

A novel mechanism of high-level, broad-spectrum antibiotic resistance caused by a single base pair change in Neisseria gonorrhoeae.

Ohneck EA, Zalucki YM, Johnson PJ, Dhulipala V, Golparian D, Unemo M, Jerse AE, Shafer WM.

MBio. 2011 Sep 20;2(5). pii: e00187-11. doi: 10.1128/mBio.00187-11. Print 2011.

38.

Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections.

Jerse AE, Wu H, Packiam M, Vonck RA, Begum AA, Garvin LE.

Front Microbiol. 2011 Jul 1;2:107. doi: 10.3389/fmicb.2011.00107. eCollection 2011.

39.

Experimental Gonococcal Infection in Male Volunteers: Cumulative Experience with Neisseria gonorrhoeae Strains FA1090 and MS11mkC.

Hobbs MM, Sparling PF, Cohen MS, Shafer WM, Deal CD, Jerse AE.

Front Microbiol. 2011 May 31;2:123. doi: 10.3389/fmicb.2011.00123. eCollection 2011.

40.

Vaccines for gonorrhea: can we rise to the challenge?

Zhu W, Chen CJ, Thomas CE, Anderson JE, Jerse AE, Sparling PF.

Front Microbiol. 2011 Jun 3;2:124. doi: 10.3389/fmicb.2011.00124. eCollection 2011.

41.

Chlamydial infection increases gonococcal colonization in a novel murine coinfection model.

Vonck RA, Darville T, O'Connell CM, Jerse AE.

Infect Immun. 2011 Apr;79(4):1566-77. doi: 10.1128/IAI.01155-10. Epub 2011 Jan 18.

42.

Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection.

Feinen B, Jerse AE, Gaffen SL, Russell MW.

Mucosal Immunol. 2010 May;3(3):312-21. doi: 10.1038/mi.2009.139. Epub 2010 Jan 27.

43.

Opacity proteins increase Neisseria gonorrhoeae fitness in the female genital tract due to a factor under ovarian control.

Cole JG, Fulcher NB, Jerse AE.

Infect Immun. 2010 Apr;78(4):1629-41. doi: 10.1128/IAI.00996-09. Epub 2010 Jan 25.

44.

Functional characterization of antibodies against Neisseria gonorrhoeae opacity protein loops.

Cole JG, Jerse AE.

PLoS One. 2009 Dec 1;4(12):e8108. doi: 10.1371/journal.pone.0008108.

45.

Mouse strain-dependent differences in susceptibility to Neisseria gonorrhoeae infection and induction of innate immune responses.

Packiam M, Veit SJ, Anderson DJ, Ingalls RR, Jerse AE.

Infect Immun. 2010 Jan;78(1):433-40. doi: 10.1128/IAI.00711-09. Epub 2009 Nov 9.

46.

Hydrogen peroxide-producing lactobacilli inhibit gonococci in vitro but not during experimental genital tract infection.

Muench DF, Kuch DJ, Wu H, Begum AA, Veit SJ, Pelletier ME, Soler-García AA, Jerse AE.

J Infect Dis. 2009 May 1;199(9):1369-78. doi: 10.1086/597390.

48.

Local and humoral immune responses against primary and repeat Neisseria gonorrhoeae genital tract infections of 17beta-estradiol-treated mice.

Song W, Condron S, Mocca BT, Veit SJ, Hill D, Abbas A, Jerse AE.

Vaccine. 2008 Oct 23;26(45):5741-51. doi: 10.1016/j.vaccine.2008.08.020. Epub 2008 Aug 30.

49.
50.

Supplemental Content

Loading ...
Support Center